After a mean follow-up of 34 months (range 6-161 months) 52% of 162 patients with refractory epilepsy (mostly with partial seizures) continue on add-on Vigabatrin treatment. Ten percent are seizure-free and an additional 12% achieved a greater than 75% reduction in seizures frequency. None of the patients with generalized epilepsies responded. Only 11% discontinued treatment because of adverse effects, usually within the first 6 months.
|Translated title of the contribution||Long term efficacy and tolerability of Vigabatrin as add-on treatment in adult refractory epilepsy|
|Number of pages||3|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Issue number||99 SUPPL. 1|
|Publication status||Published - 1997|
ASJC Scopus subject areas
- Clinical Neurology